行情

INCY

INCY

因塞特医疗
NASDAQ

实时行情|Nasdaq Last Sale

90.56
-1.48
-1.61%
盘后: 90.40 -0.16 -0.18% 19:39 01/15 EST
开盘
91.64
昨收
92.04
最高
92.52
最低
89.32
成交量
93.02万
成交额
--
52周最高
110.37
52周最低
62.48
市值
198.05亿
市盈率(TTM)
-57.6962
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
与竞争对手相比,Incyte Corp.的股票周五表现不佳
Shares of Incyte Corp. slid 1.61% to $90.56 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 2天前
Incyte Corp. stock underperforms Thursday when compared to competitors
Shares of Incyte Corp. dropped 0.75% to $92.04 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...
marketwatch.com · 3天前
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
Zacks.com · 4天前
Janus Kinase (JAK) Inhibitors Market Analysis Size, Share, Growth rate, Company Overview, Key Players, Revenue, Trends, Organizations, Opportunities, and Forecast by 2023 | Latest Research Report by Market Reports World
Jan 14, 2021 (The Expresswire) -- Global "Janus Kinase (JAK) Inhibitors Market" (2021) thoroughly scrutinizes the effects of a wide range of factors...
The Express Wire · 4天前
Global Essential Thrombocythemia Drug Market Research Report: Size, Share, Growth, Trends and Forecast 2026
Jan 14, 2021 (The Expresswire) -- Global “Essential Thrombocythemia Drug Market” Market study report covers the global and regional market with an in-depth...
The Express Wire · 4天前
Incyte Corp. stock falls Wednesday, underperforms market
Shares of Incyte Corp. slid 1.66% to $92.74 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 4天前
每日生物技术动向:博士伦健康发布积极的预公告,Acorda简化运营
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)
Benzinga · 5天前
每日生物技术动向:博士伦健康发布积极的预公告,Acorda简化运营
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) * AbbVie Inc (NYSE: ABBV) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * AtriCure Inc. (NASDAQ: ATRC) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BIOLASE Inc (NASDAQ: BIOL) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) * CareDx Inc (NASDAQ: CDNA) * Celsius Holdings, Inc. (NASDAQ: CELH) * DermTech Inc (NASDAQ: DMTK) * Dyne Therapeutics Inc (NASDAQ: DYN) * Edap Tms SA (NASDAQ: EDAP) * Evelo Biosciences Inc (NASDAQ: EVLO) * EXACT Sciences Corporation (NASDAQ: EXAS) * Eyenovia Inc (NASDAQ: EYEN) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Guardant Health Inc (NASDAQ: GH) (reacted to presentation at the JPMorgan Healthcare Conference) * Intra-Cellular Therapies Inc (NASDAQ: ITCI) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Laboratory Corp. of America Holdings (NYSE: LH) * Merus NV (NASDAQ: MRUS) (announced presentation of Phase 1 data for MCLA-158 in metastatic colorectal cancer) * OncoSec Medical Inc (NASDAQ: ONCS) * Pacira Biosciences Inc (NASDAQ: PCRX) * PRA Health Sciences Inc (NASDAQ: PRAH) * Provention Bio Inc (NASDAQ: PRVB) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syneos Health Inc (NASDAQ: SYNH) * Travere Therapeutics Inc (NASDAQ: TVTX) * Vericel Corp (NASDAQ: VCEL) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan. 12) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Lexaria Bioscience Corp. (LXRP) (the company's shares uplisted to Nasdaq and it also announced a $9.6 million public offering) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Acorda to Sell Parkinson's Disease Drug Manufacturing Facility, Reduce 16% of Workforce Acorda Therapeutics Inc (NASDAQ: ACOR) announced a definitive agreement to sell its Inbrija manufacturing operations in Chelsea, Massachusetts to Catalent Inc (NYSE: CTLT) for $80 million in cash.In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package Inbrija for Acorda. As part of the deal, Catalent will absorb all Acorda employees who work at the Chelsea facility, and certain Acorda employees at the company's Waltham, Massachusetts facility.Acorda also announced a corporate restructuring to reduce costs and focus its resources on Imbrija. In addition to the associates who will transition to Catalent, Acorda is reducing its combined Ardsley, Waltham and field headcount by approximately 16% through a reduction in force.Acorda also said it entered into an at-the-market offering agreement with H.C. Wainwright & Co., for offering common stock having an aggregate value of up to $15.25 million.Acorda shares jumped 59.91% to $6.78 in premarket trading Wednesday.Morphosys, Incyte Announce Canadian Regulatory Submission For Blood Cancer Combo Treatment Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said Health Canada has accepted the new drug submission for tafasitamab, an anti-CD19 antibody, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.Incyte has exclusive commercialization rights for tafasitamab outside of the U.S. and, if approved, Incyte will hold the marketing authorization for tafasitamab in Canada.Travere Gets Orphan Drug Designation For Sparsentan In Rare Kidney Disorder Travere announced that the FDA has granted orphan drug designation to sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that causes end-stage kidney disease. Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.DermTech's Non-invasive Melanoma Genomic Test Recommended by National Comprehensive Cancer Network DermTech said non-invasive genomic patch testing for melanoma, like DermTech's pigmented lesion assay, has received a recommendation from the National Comprehensive Cancer Network. The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice Guidelines in Oncology for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.The stock gained 12.46% to $41.61 in after-hours trading.Amgen In-licenses Autoimmune Disorder Programs For Over $240M Amgen, Inc. (NASDAQ: AMGN) executed a license and collaboration agreement with EVOQ Therapeutics for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies.Mersana Shares Gain On Insider Buying Mersana Therapeutics Inc (NASDAQ: MRSN) shares gained after a filing with the SEC revealed that Andrew Hack, a member of the board, bought 250,000 shares in the company.The stock added 7.34% to $19.45 in after-hours trading.Preannouncements Ahead of the presentation at the JPMorgan Health Conference Bausch Health Companies Inc (NYSE: BHC) said it expects fourth-quarter revenues to be greater than $2.20 billion. For the full year of 2020, the company expects to report revenues above the high-end of its revenue guidance range of $7.8 billion-$8 billion.Analysts, on average, estimate expect revenues of $2.12 billion for the fourth quarter and $7.94 billion for the full year.The company also guided to strong adjusted EBITDA.In after-hours trading, the stock rose 5.67% to $24.80.Neuronetics Inc (NASDAQ: STIM) preannounced fourth-quarter revenues of $15 million to $15.5 million, ahead of the guidance of $13 million and $13.5 million. For the full year, revenues are estimated between $48.7 million and $49.2 million. The consensus estimates call for revenues of $13.24 for the fourth quarter and $46.93 for the full year.The stock rallied 14.82% to $13.40 in after-hours trading.Clearpoint Neuro Inc (NASDAQ: CLPT) preannounced above-consensus revenues for the fourth quarter and full year.The stock was up 3.43% to $15.99 in after-hours trading.Offerings Provention Bio Inc (NASDAQ: PRVB) said it has commenced an underwritten public offering of 6 million shares of its common stock. All of the shares to be sold in the offering are to be sold by the company.The stock fell 10.03% to $17.50 in after-hours trading.Affimed NV (NASDAQ: AFMD) announced the commencement of an underwritten public offering of its common shares. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the company added.In the after-hours session, the stock slipped 7.85% to $6.10.See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 5天前
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解INCY最新的财务预测,通过INCY每股收益,每股净资产,每股现金流等数据分析因塞特医疗近期的经营情况,然后做出明智的投资选择。
分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测INCY价格均价为105.69,最高价位133.00,最低价为89.00。
EPS
机构持股
总机构数: 793
机构持股: 2.17亿
持股比例: 99.12%
总股本: 2.19亿
类型机构数股数
增持
174
562.71万
建仓
129
84.35万
减持
181
944.07万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/President/Chief Executive Officer/Director
Herve Hoppenot
Chief Financial Officer/Executive Vice President
Christiana Stamoulis
Executive Vice President/Chief Scientific Officer
Dashyant Dhanak
Executive Vice President/General Counsel
Maria Pasquale
Executive Vice President/Director of Human Resources
Paula Swain
Executive Vice President
Barry Flannelly
Executive Vice President
Vijay Iyengar
Executive Vice President
Steven Stein
Executive Vice President
Wenqing Yao
Lead Director/Independent Director
Julian Baker
Independent Director
Jean-Jacques Bienaime
Independent Director
Paul Clancy
Independent Director
Wendy Dixon
Independent Director
Jacqualyn Fouse
Independent Director
Paul Friedman
Independent Director
Edmund Harrigan
Independent Director
Katherine High
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
INCY 简况
Incyte Corporation是一家生物医药公司。该公司专注于探索及开发医学治疗方案(主要为肿瘤治疗)并将其商业化。该公司专注于探索两面神激酶(JAK)抑制剂的研究及开发计划。该公司的产品包括不同研发阶段(前临床研究期及开发后期)的复方药以及已上市产品JAKAFI(ruxolitinib)。该公司已开发多种强效的、具有生物可用性的口服JAK抑制剂。其JAK抑制剂可以选择性抑制JAK1或抑制JAK1及JAK2。JAKAFI是在JAK计划中研制出的复方药,一种JAK1及JAK2的口服抑制剂。JAKAFI罕用药适用于骨髓纤维化(MF)、真性红细胞增多(PV)以及原发性血小板增多症。Baricitinib是该公司的第二种JAK1及JAK2口服抑制剂。
展开
热门股票
代码
价格
涨跌幅

微牛提供Incyte Corporation(NASDAQ-INCY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的INCY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易INCY股票基本功能。